The DOI matches its Crossref record.
Pathways of Coagulation/Fibrinolysis Activation in Malignancy
Abstract
Recent progress in elucidating the complex and heterogeneous interactions between malignancy and coagulation or fibrinolysis reactions in humans has clarified the pathogenesis of disseminated intravascular coagulation that occurs with malignancy and has revealed evidence for two distinct pathways of growth regulation based on production by tumor cells of initiators of thrombin formation versus plasminogen activators. We have proposed a preliminary classification of tumors (see Table 2) based on these interactions. Type I tumors are those in which the tumor cells are associated with an intact coagulation pathway that leads to thrombin formation at the tumor periphery but in which the tumor cells lack u-PA. Examples of tumors in this category include SCCL, malignant melanoma, and renal cell carcinoma. Type II tumors are those in which the tumor cells express u-PA but lack an associated coagulation pathway leading to thrombin formation. Examples of type II tumors include prostate cancer, colon cancer, breast cancer, and N-SCLC. Type III tumors are those that express neither of these pathways, or exhibit some other pattern of interaction. Obviously, this formulation must be regarded as hypothetical. However, this concept fits with the limited data available to date from clinical trials. More importantly, this hypothesis can be tested further by means of intervention aimed at interrupting pathways relevant to specific tumor types. Characterization of additional tumor types by the methods described should permit amplification of this classification of tumors and other patterns of interaction may be defined. Exploration of the coagulation-cancer interaction holds considerable promise for gaining new understanding of both the coagulation mechanism and tumor biology. Most intriguing is the prospect that imaginative approaches to cancer treatment may be devised that are not only relatively nontoxic and low cost, but also effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Venous thromboembolism and cancer
Baron, J. A., Gridley, G., Weiderpass, E., Nyren, O., & Linet, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10018-6 · Cited by 513
Platelets and cancer angiogenesis nexus
Wojtukiewicz, M. Z., Sierko, E., Hempel, D., Tucker, S. C., & Honn, K. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9673-1 · Cited by 257
Self-citationDowns, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01464-3 · Cited by 138
Metadata
- Authors
- Zacharski, L., Wojtukiewicz, M., Costantini, V., Ornstein, D., & Memoli, V.
- Venue
- Seminars in Thrombosis and Hemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 1992-01
- Volume
- 18
- Issue
- 01
- Pages
- 104-116
- ISSN
- 0094-6176 (ISSN-L)
- 1098-9064
- OpenAlex
- W1968462114
- Cited by
- 160
- References
- 0
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathways of Coagulation/Fibrinolysis Activation in Malignancy. https://app.cochat.ai/papers/10.1055/s-2007-1002415
- The paper
- Zacharski, L., Wojtukiewicz, M., Costantini, V., Ornstein, D., & Memoli, V. (1992). Pathways of Coagulation/Fibrinolysis Activation in Malignancy. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/s-2007-1002415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.